DE:YP1B Stock Latest News
Company AnnouncementsImmutep Reports Positive Phase I Data for Autoimmune Candidate IMP7615d ago
Company AnnouncementsImmutep to Present Efti Trial Data at Two Oncology Congresses1w ago
Company AnnouncementsImmutep Refocuses Efti Development, Elevates IMP761 as Cash Runway Extends to 20282w ago
Company AnnouncementsImmutep Sets Date and Agenda for 2026 Annual General Meeting2w ago
Company AnnouncementsImmutep Files Updated Corporate Governance Disclosures for FY20262w ago
Company AnnouncementsImmutep’s Sarcoma Trial Shows Stable Quality of Life and Post-Surgery Gains3w ago
Company AnnouncementsImmutep’s First-in-Class LAG-3 Agonist IMP761 Secures Late-Breaking Slot at ACR 20263w ago
Company AnnouncementsImmutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change1M ago
Company AnnouncementsImmutep Moves to Restore ASX Audit Committee Compliance After Director Exit1M ago
Company AnnouncementsImmutep Details Equity Interests of Departing Director Pete Meyers1M ago
Company AnnouncementsImmutep Reports Lapse of 2 Million Performance Rights1M ago
Company AnnouncementsImmutep Announces Board Resignation and Search for New Non-Executive Director1M agoCompany AnnouncementsImmutep Director Increases Shareholding Through Performance Rights Exercise1M ago






